Vertex Pharmaceuticals and Crinetics Pharmaceuticals, a global pharmaceutical company focused on the discovery, development and commercialisation of novel therapeutics for endocrine diseases, have entered into a definitive agreement under which Vertex will acquire Crinetics for approximately $10 billion.
The transaction was unanimously approved by both the Vertex and Crinetics boards of directors and is anticipated to close in the third quarter of 2026.
Crinetics’ marketed medicine, Palsonify (paltusotine), received approval from the US Food and Drug Administration (FDA) in September 2025.
Palsonify was recently approved by the European Medicines Agency (EMA) and is under review by other global regulatory bodies.
It is the first and only once-daily oral therapy for adults with acromegaly, a rare and debilitating condition caused by a pituitary tumour that secretes excess growth hormone, which affects an estimated 20,000 diagnosed people in the US Palsonify leads to rapid disease control and normalisation of key disease markers in both treatment-experienced and untreated populations. Since launch, Palsonify has demonstrated promising early commercial momentum, supported by strong demand across all patient segments, prescribing activity expansion and growing reimbursement coverage, all of which reinforce its potential to redefine the treatment paradigm in acromegaly.
Crinetics’ most advanced pipeline candidate, atumelnant, is a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist currently in phase 3 development for congenital adrenal hyperplasia (CAH).
